Spinal Cord Injury Neuroprotection With Glyburide (SCING): Pilot Study: An Open-Label Prospective Evaluation of the Feasibility, Safety, Pharmacokinetics, and Preliminary Efficacy of Oral Glyburide (DiaBeta) in Patients With Acute Traumatic Spinal Cord Injury
Latest Information Update: 17 Oct 2024
At a glance
- Drugs Glibenclamide (Primary)
- Indications Spinal cord injuries
- Focus Adverse reactions; Therapeutic Use
- Acronyms SCING
- 20 Oct 2022 Status changed from not yet recruiting to recruiting.
- 13 Oct 2022 Planned initiation date changed from 1 Sep 2022 to 1 Nov 2022.
- 20 Jul 2022 Planned initiation date changed from 1 Jun 2022 to 1 Sep 2022.